Dr. Benjamin Tomlinson, MD
Claim this profileUniversity Hospitals of Cleveland
Studies Myelodysplastic Syndrome
Studies Acute Myelogenous Leukemia
9 reported clinical trials
14 drugs studied
Affiliated Hospitals
Clinical Trials Benjamin Tomlinson, MD is currently running
Decitabine + Venetoclax
for Acute Myeloid Leukemia Maintenance Therapy
The goal of this interventional clinical trial is to determine if low doses of gentle chemotherapy after bone marrow transplant may prevent relapse and promote an increase in survival and decrease in side effects in participants with acute myeloid leukemia and myelodysplastic syndromes. The main question it aims to answer is whether or not providing a new, gentler way of administering chemotherapy will help control leftover cancer with minimal side effects. This treatment involves decitabine and venetoclax. Participants will receive standard post-transplant care. Participants will be administered decitabine once per week with normal transplant follow up visits, and then will take a venetoclax pill about 6 to 8 hours later. Participants will meet their study team at the beginning, midway, and at the end of the trial to receive bone marrow testing. Participants will receive treatment until either one year of therapy, relapse, or recurrent dose limiting toxicity (DLT) despite dose reduction.
Recruiting1 award Phase 1 & 219 criteria
5-Azacitidine + Decitabine
for Myelodysplastic Syndrome
Another term for myelodysplastic syndrome is bone marrow failure. The bone marrow is where components of blood such as red cells, platelets and white cells are made. In bone marrow failure, the ability for bone marrow to make these cells is decreased. In myelodysplastic syndrome, this decreased bone marrow function is believed to result from abnormalities that prevent the normal maturation process by which bone marrow cells develop into red blood cells, white blood cells and platelets. In myelodysplastic syndrome, these abnormal bone marrow cells occupy space in the bone marrow and prevent the function of remaining normal bone marrow cells. One approach to treating the abnormal growth of immature cells is to give chemotherapy which damages DNA within these cells and causes their death. Unfortunately, such therapy has side-effects, since even normal cells can be affected by the treatment. Both 5-azacitidine (5AZA) and decitabine (DEC) are FDA-approved to treat MDS. In this study, 5AZA and DEC will be administered using an alternating low doses schedule in an attempt to overcome the known mechanisms of resistance to the administration of 5AZA or DEC as single agents caused by automatic adaptive shifts in DNA metabolism.
Recruiting3 awards Phase < 14 criteria
More about Benjamin Tomlinson, MD
Clinical Trial Related1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Benjamin Tomlinson, MD has experience with
- Decitabine
- Cyclophosphamide
- Fludarabine
- Venetoclax
- 5-azacytidine
- Fully Human Anti CD19 CAR-T Cell Dose
Breakdown of trials Benjamin Tomlinson, MD has run
Myelodysplastic Syndrome
Acute Myelogenous Leukemia
Acute Myeloid Leukemia
Mixed-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Benjamin Tomlinson, MD specialize in?
Benjamin Tomlinson, MD focuses on Myelodysplastic Syndrome and Acute Myelogenous Leukemia. In particular, much of their work with Myelodysplastic Syndrome has involved treating patients, or patients who are undergoing treatment.
Is Benjamin Tomlinson, MD currently recruiting for clinical trials?
Yes, Benjamin Tomlinson, MD is currently recruiting for 3 clinical trials in Cleveland Ohio. If you're interested in participating, you should apply.
Are there any treatments that Benjamin Tomlinson, MD has studied deeply?
Yes, Benjamin Tomlinson, MD has studied treatments such as Decitabine, Cyclophosphamide, Fludarabine.
What is the best way to schedule an appointment with Benjamin Tomlinson, MD?
Apply for one of the trials that Benjamin Tomlinson, MD is conducting.
What is the office address of Benjamin Tomlinson, MD?
The office of Benjamin Tomlinson, MD is located at: University Hospitals of Cleveland, Cleveland, Ohio 44106 United States. This is the address for their practice at the University Hospitals of Cleveland.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.